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Abstract. Influenza A virus is a major threat to human health and 
a potential biowarfare pathogen. The M2 proton channel protein, 
essential for virus viability, contains a single transmembrane 
domain that forms a homo-tetrameric pore, targeted by 
Amantadine. The emergence of resistance to drugs poses major 
health risk as most of Influenza virus isolates are now 
Amantadine-resistant. Although only a handful of mutations are 
tolerated in transmissible viruses, V27A, S31N and L26F, they are 
enough to jeopardize public health. Aiming to overcome drug 
resistance, we are preparing new polycyclic small molecules 
which putatively will inhibit the wild-type and the mutant M2 
channels.  
     
1. The Influenza A virus 
 
      The influenza A virus, commonly known as the Flu virus, is a coated virus 
of the Orthomyxoviridae family, which has a multipartite, negative-sense, 
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single-stranded RNA genome that codes for 11 viral proteins. From the 
exterior to the interior of the virus, we find the following proteins: the 
hemagglutinin (HA) and the neuraminidase (NA), which are antigenic 
glycoproteins found in the lipid membrane of the virus; the M2 protein, 
which crosses the lipid coating in the form of a proton selective channel. In 
the viral interior, we find the nucleoprotein (NP), the matrix protein M1, 
the viral polymerase complex formed by the PA, PB1 and PB2, subunits, 
the non-structural protein NS1 and the nuclear export protein (NEP) [1]. 
 The standard nomenclature of the viral strains includes: viral type/ 
specie from isolation (in case of non-human)/ isolation place/ number of 
isolate/ year of isolation/ hemagglutinin type/ neuraminidase type [2]. For 
example A/Panama/2007/1999(H3N2) indicates an Influenza A virus 
found in humans in Panama, that is the number of isolate 2007 of the year 
1999 and that has a HA type 3 and a NA type 2.  
 The two most relevant traits of the Influenza A virus are its high 
infectivity, which is responsible for its easy transmission through the 
airborne route or via hands-mouth, and its ability to mutate [3]. The viral 
mutations occur through two mechanisms: the antigenic drift, which 
consists in point mutations in the viral structure, that allow a slight 
variation of the viral properties and is responsible, for example, of the drug 
resistance mechanism. The other mutation path is the antigenic shift, which 
consists in the genetic rearrangement between two or more different 
influenza A viral strains, giving place to a new strain with mixed 
properties. For example, through this mechanism, an animal virus can 
acquire the capacity to infect humans [4]. 
 
2. The viral cycle 
 
 Viral entry. The cycle starts when the virus enters in the organism and 
recognizes the sialic acids located on the surface of the  host’s respiratory 
system epithelial cells, to which is attached thanks to the surface protein 
HA [5]. 
 Endocytosis. Following, the virus enters into the cells through a 
receptor-mediated endocytosis, usually by clatrine, even alternative 
internalization routes as macropinocytosis [6] have been reported. The 
virus, hence, is internalized in a primary endosome with a pH around 6. 
 Fusion. The primary endosome is transported giving place to a late 
endosome in which the pH is again lowered thanks to the vacuolar ATPase 
(V-ATPase). This promotes an irreversible conformational change of the 
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HA, in which the N-terminus of the HA2 subunit, known as fusion peptide 
[7-8], is expelled. This fusion peptide will be inserted in the endosomal 
membrane, giving place to the fusion of both membranes, the viral and the 
endosomal one. The same pH shift also activates the M2 channel, which 
starts conducting protons, acidifying the viral interior. This will give place 
to the dissociation of the M1 protein from the viral ribonucleoprotein 
complex (vRNP), allowing the release of the vRNP to the cytoplasm from 
where they will be imported to the nuclei through the nuclear import 
factors. On another hand, the M1 protein will complex in late endosomes 
to be, in a similar way, imported to the nuclei [9]. 
 Viral replication and transcription. Once in the nuclei the viral 
polymerase catalyzes the synthesis of one copy in positive sense of the 
viral RNA – the so-called complementary RNA, which will be copied to 
produce big quantities of viral RNA (vRNA) and the synthesis of a 
messenger RNA, of positive sense. The new vRNA will be encapsulated 
by the nucleoprotein and thanks to the NEP, the nuclear export complex 
will be formed; this will allow the crossing of one of the nucleoproteins to 
the cytoplasm. On another side, the mRNA will attach to the nucleoprotein 
to be exported through the nuclear export factor 1 (NXF1), which is the 
machinery that the host cell uses for its own RNA. 
 Translation. The mRNA highjacks the host cell translation 
mechanisms thanks to the NS1 protein, avoiding the response mechanisms 
of the host [10]. Once released from the NP, the mRNA are translated for 
viral proteins in the ribosomes. The NP, NS1, NEP and the M1 protein 
return to the nuclei to give place to more viral RNA. In contrast the NA, 
HA and the M2 protein will be transported to the endoplasmic reticulum 
and the Golgi apparatus where post-translational modifications will take 
place, giving mature proteins. Worthy of mention, during the transit 
through the Golgi apparatus – which has an acidic pH – the M2 protein is 
responsible of increasing the pH in the interior of the transport vesicles, to 
avoid the HA conformational change [11]. 
 Packaging, virion formation and release of mature virus. Once the 
maturation process of the surface proteins HA, NA and the transmembrane 
protein M2 are completed, those proteins aggregate in the plasma 
membrane lipid rafts. Following, the viral RNA will attach to the HA, 
thanks to the action of the M1 protein. The high concentration of HA and 
NA, will alter the membrane curve, allowing the polymerization of the 
protein M1, in order to continue with the formation of the new virion. 
Simultaneously the M2 protein passes to the neck of this virion, altering 
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once again the plasma membrane, until this is separated from the virion 
[12] which will remain attached to the host cell uniquely by bonds of the 
HA with the sialic acid receptors. Finally, thanks to the scission of this 
bond by the NA, the newly formed influenza virus will be released [13]. 
 As can be deduced from the viral cycle, all the Influenza A proteins 
play a paramount role. Hence, the malfunction or inhibition of any of 
those, will allow stopping the infection; consequently, all of them are 
subject to be used as anti-influenza A drug targets [14]. 
 
3. The M2 channel 
 
3.1. Structure 
 
 The M2 viroporin of the Influenza A virus is a 97 amino acid 
transmembrane protein that assembles in tetramers to give place to a 
channel across the viral membrane. Each strand consists in two α-helixes 
with a left-handed parallelism respect the N-terminal region. This deviation 
is due to a slight tilt of 30-35º nearby the Gly 34 [15]. The following 
regions can be distinguished in each strand: 
 Residues 1 to 24 – N-terminus: Extracellular unstructured region, 
which function is the incorporation of the protein into the virion.  
 Residues 25 to 46 – Transmembrane domain [16]: Tetramer of                  
α-helixes, which is responsible for the proton conduction. The                   
drug-binding site is located in this region. 
 Residues 47 to 61 – Amphipathic cytoplasmic region: Intracellular,              
α helix structured domain that is responsible for the stabilization of the M2 
protein and the release and scission of the newly formed virions. 
 Residues 62 to 97 – C-terminus: Intracellular unstructured region 
where the interaction with the matrix viral protein M1 takes place [17]. 
 Since the structure of the M2 protein was solved in 2008 – by solution 
NMR [18] and X-Ray crystallography [19] - up to 15 different structures 
can be found in the Protein Data Bank (PDB). Nevertheless was not until 
2014 that the M2 was assessed as a 2-fold symmetric tetramer, which can 
be better described as a dimerization of functional dimers [20-21]. 
 
3.2. Function
 
 
 The main function of the M2 channel is to allow the proton flow in a 
controlled manner [15]. It acts as a pH regulator in order to allow, during 
the viral life cycle: i) the proton diffusion to the interior of the endosome, 
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where the virus is contained to reach a mature state, allowing the fusion of 
the viral membrane in the endosome and the right unpacking of the viral 
genome of the protein M1 [22] and, ii) the delay of the acidification of the 
transport vesicles in the Golgi apparatus to ensure the correct formation 
and the later release of the virus [23]. 
 The transmembrane domain of the channel (residues 25 – 46) is the 
functional unit, as it contains the essential residues for the proton 
conduction. These are: the histidines in position 37 (His37), the pKa of 
which controls the conduction rate [24-25]; the tryptophans in position 41 
(Trp41), which ensure the unidirectional proton flow [26]; the valine in 
position 27 (Val27), which forms a small valve to control the proton 
entrance to the channel, and the aspartic acid in position 44 (Asp44), 
which forms an indirect hydrogen bond with the NH group of the indole 
ring of Trp41 through a water net, at the end of the channel. Hence, 
meanwhile the motif HxxxW formed by H37 and W41 is the functional 
core of the channel, the V27 and the D44 are the gates veiling it.  
 The M2 is a slow channel as at physiological pH (pH=7.4) conducts at 
a rate of 10
2
-10
3
 protons per second, considered slow with respect of the 
constant of proton conduction through an aqueous pore of similar 
dimensions: 10
8
 protons per second [27]. This fact is due that at 
physiological pH the concentration of protons is low, around one order of 
magnitude below the diffusion rate, however, when the external pH is 
lowered below the viral internal pH (pHout < pHin), this rate becomes much 
higher, until multiplying the diffusion rate by a second order rate constant. 
Hence, the conduction peak is found at low pHs [28]. This behaviour is the 
responsible for the sigmoidal dependence of the pH by conduction of 
protons through the M2 channel. 
 The mechanism through which the proton conduction occurs has been 
object of controversy in the last years [15, 29-33]. Despite this, the 
determination of the double dimeric structure has allowed a plausible 
explanation [20-21].  The protons enter the channel through the V27 gate. 
Once in the hydrophilic interior the protons are transported through an 
intermolecular translocation, thanks to the proximity of the hydrophilic 
residues that are facing the pore. 
 On a first instance the protons attach to the more N-terminal H37 and 
after to the more C-terminal one of the dimers which are forming an H2 
bond between the nitrogens δ i ε respectively. Following, the proton transfer  
Marta Barniol-Xicota & Santiago Vázquez 138 
 
 
Figure 1. Schematic representation of the TM domain of the influenza A M2 
channel. The side chains of the relevant residues V27, N31, H37 and W41 are shown. 
For clarity, only three of the four chains are shown. 
 
from the His to the Trp occurs and the proton is then released to the viral 
interior. Thanks to a His37 tautomery, the protein returns to the original 
state. Hence, each of the dimers that form the channel is functional for the 
proton conduction [33]. It is important to highlight that the proximity 
between the H37 and the W41 – which form a stable net of cation−π 
interactions inside the helix and between neighbouring helixes - is the 
responsible of the protein tetramerization.  
 
4. Related diseases 
 
 The influenza disease, commonly known as the flu, consists in an 
incubation period of two days, after which the signs and symptoms appear 
giving: high fever, headache, muscle and joint pain, general malaise and 
respiratory symptoms. Medical attention to recover from the flu for 
otherwise healthy patients is not usual, as symptoms normally disappear 
within a week. However, it can be especially aggressive giving fatal 
complications, among high-risk groups (children younger than two years 
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old, the elders and the immunosuppressed) or by a high virulent strain. 
Seasonal influenza outbreaks occur every year during autumn and winter 
in temperate regions, as there are the suitable conditions of relative 
humidity and temperature. Worldwide, these annual epidemics result in 
about 3 to 5 million cases of severe illness and about 250.000-500.000 
deaths, being a clear public health treat [34]. In addition, the flu can cause 
serious economic losses arising from work absenteeism, productivity 
decrease, and saturation of health clinics during the peak illness periods 
[35]. 
 However, the most important concern is the capacity of this virus to 
generate pandemics. These can occur through the antigenic shift, through 
which an especially infectious strain can combine with a highly 
transmissible one, giving place to a lethal unstoppable pandemic, as 
happened in 1918 with the Spanish Flu. The 1918 pandemic terminated 
with 40 million of lifes around the globe, being the most devastating of 
humankind history [36]. Taking this into account and knowing that those 
pandemics have a periodicity, the need to develop drugs to fight this virus 
is of vital urgency. 
  
5. M2 channel- drug Pipeline  
 
 The M2 channel is the target of two clinically approved drugs: 
amantadine (Symmetrel
®
, Mantadix
®
) and rimantadine (Flumadine
®
). 
 The mechanism of action of amantadine (Amt) was object of debate in 
the past [37], however, nowadays it is acknowledged that only one                   
Amt molecule binds the interior of the pore, between the residues Val27 and  
 
 
 
Figure 2. Commercial drugs targeting the M2 channel and corresponding IC50. 
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Gly34 (called pore binding site), when the channel is in the open state, under 
acidic pH. The mechanism through which these adamantane structures 
inhibit the channel activity, responds to a physical blockade in which the 
drug occludes the pore avoiding: the proton transfer, the conformational 
change of the protein and the protein tetramerization. 
 The orientation of the polar group of the adamantane in the M2 channel 
had been debated as well. The two main theories were: the binding occurs in 
the down form [38], in which the hydrophobic cage is interacting through 
van der Waals forces with the methyl groups of the Val27 and Ala30, 
meanwhile the polar group is directed to the interior of the pore. Contrarily, 
in the second modality or up binding mode, the polar group is pointing the 
Val27 gate, being better solvated. The debate ended after proving that these 
two binding modes fluctuate depending on the protonation state of the M2 
[39]. 
 
6. M2 as a therapeutic target  
 
 Nowadays the appearance of resistant strains together with the 
secondary effects in the central nervous system of Amt – known as NMDA 
receptor antagonist – have prompted the use of these drugs to be discouraged 
[40]. Surprisingly instead of causing a desertion of the M2 channel, has 
unchained a strong research on this protein, as it is the ideal candidate to be a 
drug target, presenting: 
 
 Well known biology. Nowadays the M2 channel is the best-known 
channel, being an ideal candidate for the rational drug design. 
 Essential for the viral cycle. As aforementioned, M2 channel is 
responsible for pH regulation in several events of the viral cycle. If the 
proton flow is stopped by a suitable inhibitor, the virus is no longer able to 
replicate. 
 Low mutation rate. Despite the flu virus has a high mutagenicity rate, in 
the case of the M2 channel, a very limited number of mutants that are both, 
infective and viable are known. In fact, in the circulating strains we mainly 
find the following 3 types [41]: 
 
V27A  (Valine    Alanine) 
 In this mutant channel in the position 27 the valine, which side chain is 
an isopropyl group, is replaced by an alanine, with a methyl group as a side 
chain. This destroys the entrance gate of the channel, increasing the proton 
conduction rate and weakening the α helix packing, which gives place to a        
2 Å wider channel, respect the wild-type (wt). Hence, despite the inhibitors 
are able to bind the pore, there is not enough energetic resistance to avoid 
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their exit, provoking the fast drug release from the channel and restarting the 
proton flow. Worthy of note, the V27A is the only mutant arising from the 
drug selection pressure [42-43].  
 
L26F (Leucine         Phenylalanine) 
 The replacement of the leucine, with an isobutyl group, by a 
phenylalanine, with a benzyl group, which is placed in the interhelical 
interface, destabilizes the general structure of the channel. As a result, the 
packaging of the pore will be less compact, increasing its diameter by 0.5 Å. 
The widening effects are similar to those of the V27A mutation. 
 
S31N (Serine         Asparagine) 
 The S31N mutant is clinically the most relevant [44] as it is found in a 
95% of the currently circulating strains. The serine (-CH2OH) of the wt 
channel is replaced by an asparagine (-CH2CONH2) giving place to a 
bigger change than in the previous cases: the channel widens 0.5 Å nearby 
the Val27 gate and narrows on 1.5 Å in the mutation site (Asn31). In the 
wt, the Ser31 is oriented towards the membrane lipids, conformation that is 
not adopted in the mutant channel, as the Asn31 methylcarboxamide side 
chain, is longer and more hydrophilic, giving place to unfavourable 
interactions. This fact provokes a global restructuration of the channel that  
 
wild type channel V27A mutant channel
 
 
Figure 3. Schematic representation of the TM domain of the wild-type M2 channel 
vs its V27A mutant. Note the cavity expansion at the top in the V27A mutant M2 
channel. 
Marta Barniol-Xicota & Santiago Vázquez 142 
destroys the Amt binding site. In the case that Amt enters the channel, it 
will stablish destabilizing interactions with the Asn31 methylcarboxamide 
side chain, oriented towards the pore in the S31N. Despite this will justify 
the resistance mechanism of S31N it needs to be mentioned that the full 
mechanism has not yet been elucidated and there are other hypotheses           
[19, 45-46].  
 
7. Our M2 oriented research line  
 
 Since the introduction of Amt in clinics in 1966 [47], hundreds of 
analogues have been synthesized and evaluated. In 2011, we reviewed the 
earlier synthetic efforts carried out before the existence of the recent 
functional, structural and computational studies that have provided a solid 
basis for structure-based drug design [48]. More recently, in 2015,               
Wang et al. updated this topic, with focus on the rationally-designed 
inhibitors [49]. 
 During the past years, our group has synthesized several polycyclic 
Amt analogues containing different scaffolds including ring-contracted, 
ring-rearranged and 2,2-dialkyl derivatives of Amt. Thanks to the growing 
knowledge of the M2 structure and function, the rational design of new 
inhibitors against the resistant strains is starting to bear fruit. In the following 
sections we will review our own work on M2 inhibitors, with focus on four 
generations of inhibitors (Figure 4). 
 
 
 
Figure 4. Summary of our M2 research line. 
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8. First Generation inhibitors 
 
 The first inhibitors prepared in our research group [50] steam from 
amine 1, which was found to be an Influenza A compound in a wide 
pharmacological activity assay of Amt ring-contracted analogues prepared in 
the group [51]. In this early project, several ring expanded and ring 
contracted derivatives of Amt were synthesized and evaluated with the aim 
to explore the effect of modifying the inhibitor’s size in the different M2 
channels (at the time of unknown structure). 
 Resulting from this first work, several inhibitors against the wt channel 
of Influenza A virus were identified. Moreover it could be seen                               
that the ring expanded analogues, featuring the                                                                 
3-azahexacyclo[7.6.0.0
1,5
.0
5,12
.0
6,10
.0
11,15
] pentadecane scaffold (5 and 6) 
were able to show marginal inhibition values against the mutant V27A. 
More interesting was the ring contracted analogue 2, which was able to 
mildly inhibit the three relevant channels of the virus [50]. 
 
 
 
Figure 5. Ring contracted and ring expanded analogues prepared in a previous 
project. Antiviral EC50 values are shown for 1. For compounds 2-6, IC50 values are 
shown for wt M2 channel, while % of inhibition of the channel function by 100 µM 
of inhibitor for 2 min, are given for A/V27A and A/S31N mutant channels. 
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Figure 6. Analogues prepared in this project. From the bisnoradamantane scaffold 
(black), the length is increased in both directions with a pyrrolidine ring (blue) and 
with a variety of alkyl substituents (red), which confer greater length and bulkiness to 
the basic centre distal side. 
 
 These results promoted a further exploration of the ring contracted 
analogues of Amt [52]. With the aim to target the three main channels we 
envisaged a series of bisnoradamantane-like scaffolds,                                       
3-azatetracyclo[5.2.1.1
5,8
.0
1,5
]undecanes, which were modified to be 
greater in length than Amt –feature that had been seen beneficial when 
targeting the wider V27A- but with a slight width reduction compared to 
this commercial drug –thought to be required to inhibit the narrower 
mutant S31N (Figure 6). 
 In addition, for this family of derivatives, the basic centre was 
introduced in a pyrrolidine scaffold. This modification had three main 
purposes: i) to increase the compound’s length in the basic centre proximal 
site; ii) to confer a fixed orientation to this basic centre, and iii) to reduce 
the conformational freedom of the basic centre. 
 
8.1. Synthetic route 
 
 We will exemplify the synthesis of compounds of general structure I-IV 
using the smaller analogues 16-18 (Scheme 2) [52]. To access dicarboxylic 
acid 14, key precursor of the depicted compounds, a synthetic route 
previously described in the group was followed [53-54] (Scheme 1). 
 The synthesis started with a Weiss reaction [55-56], which implies the 
condensation of the α‐dicarbonylic compound glyoxal with two 
equivalents of dimethyl 1,3‐acetonedicarboxylate, in basic media. 
Interestingly this unique reaction consists in two aldol condensations, two 
dehydrations and two Michael reactions that afford the bicyclic adduct 7 in  
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Scheme 1. Preparation of the key bisnoradamantane diacid 14 
 
moderate yields. The dienol‐tetraester 7 is then treated with acetic and 
hydrochloric acids in water, undergoing a hydrolysis and decarboxylation 
to the symmetric diketone 8 [57]. In aqueous media with neutral                       
pH - regulated by dropwise addition of 40% sulphuric acid - the diketone 
intermediate was reacted with potassium cyanide to give a stereoisomeric 
mixture of bis-cyanohydrines. This mixture was readily dehydrated using 
thionyl chloride in pyridine at reflux, to the regioisomeric mixture of 
dinitriles 9 and 10. After sublimation of the mixture of 9 and 10, in order 
to remove sulfur traces, a catalytic hydrogenation, using 10 % Pd/C as 
catalyst and 20 atm of pressure, yielded the stereoisomeric mixture 11, 
composed of the three possible reduced products. Following, this mixture 
was hydrolysed with KOH in a methanol/water media and the bicyclic 
diacid obtained was immediately esterified, using Fisher’s conditions, to 
the regiomeric ester mixture 12. Upon reaction of 12 with the basic                                   
non-nucleophile lithium diisopropylamide (LDA), the lithium bis‐enolates 
were coupled by a iodine-mediated oxidation. This cyclization step was 
key in order to build up the bisnoradamantane scaffold, immediate 
precursor of the target compounds. 
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 A final hydrolysis in basic media furnished the desired 
bisnoradamantane diacid 14, upon which we started the envisaged 3-step 
synthetic route towards our first 3-azatetracyclo[5.2.1.1
5,8
.0
1,5
]undecane 
product (Scheme 2). 
 
  
 
Scheme 2. Route towards compounds 16, 17 and 18. 
 
 The reaction of 23 with urea at 180ºC furnished the imide 15, which was 
reduced using Red‐Al® to 16. From this amine 16, the guanidine derivative 
18 and the tertiary amine 17 were easily synthesized using standard 
procedures. 
 Starting from a suitably substituted diketone analog of 8, compounds 
featuring scaffolds II-IV were accessed in an analogous way [52]. 
 
8.2. Pharmacological evaluation 
 
 After pharmacological testing, this work showed that, starting from 
compounds active only against the wt A/M2 channel, it is possible to 
design compounds active against both the wt and the V27A mutant A/M2 
channels. In fact, some of them inhibit both channels more effectively than 
Amt inhibits the wt. For example, while amine 16 and guanidine 18 were 
only active against the wt A/M2 channel (IC50 = 11.7 and 1.05 M, 
respectively), the corresponding analogues derived from series IV were 
endowed with dual inhibition of the wt (e.g., IC50 = 3.4 M for the 
guanidine), and the V27A mutant (e.g., IC50 = 0.3 M for the guanidine) 
A/M2 channels. Of note, the low micromolar antiviral activity of the three 
dual inhibitors identified, amine from series IV and guanidines from series 
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II and IV, was confirmed by an influenza virus yield assay [52]. 
Interestingly, these were the first non-adamantane compounds endowed 
with this dual activity reported in the literature, opening the way to the 
design of novel M2 inhibitors structurally based on non-adamantane 
scaffolds.  
 
9. Second and third generation inhibitors 
 
 The endeavour described herein has its origins in our previous project 
(see above) in which we observed that the polycyclic amines, which were 
greater in length but featured a reduction in the polycyclic core width in 
respect to amantadine, were endowed with dual activity against the wt and 
the V27A mutant channels from Influenza A virus.  
 With the objective of further exploring this strategy and taking into 
account that: 
 
 Several structures of the M2 wt channel were available at the time [19, 29,58], 
which allowed a tailoring of our compounds to the binding site. 
 The structure of the V27A mutant had been disclosed, reporting wider 
diameters of the pore [59]. 
 Our hypothesis that, in order to target the V27A mutant, greater lengths 
might be required. Presumably this would allow the basic centre of our 
molecules to establish interactions with the Gly34 in the lower binding 
site of the channel, disrupting the deeper water clusters and blocking the 
pore [60]. 
 Coming from a resource consuming synthetic route of 12 steps, which 
included challenging reactions and the use of hazardous reagents to 
reach the first bioactive compound, this time we aimed for ready-access 
compounds, this is, the new bioactive polycycles should be prepared in 
few synthetic steps [61]. 
 
 The following three polycyclic scaffolds: 4-azatetracyclo[5.3.2.0
2,6
.0
8,10
] 
dodecanes (V), 4-azatetracyclo[5.4.2.0
2,6
.0
8.11
]tridecane (VI) and 7,8,9,10-
tetramethyl-3-azapentacyclo[7.2.1.1
5,8
.0
1,5
.0
7,10
]tridecane (VII), were 
envisaged at the start of this work (Figure 7). 
 These structures were meeting the sought criteria, being greater in length 
than our previous family of compounds and the first bioactive compound of 
each series was accessible in only 2 synthetic steps in the case of V and VI 
or 5 steps in the case of VII. In addition, these scaffolds offered diverse 
chemically modifiable points, which allowed us to prepare a family of 
derivatives for each series. 
Marta Barniol-Xicota & Santiago Vázquez 148 
 
 
Figure 7. Designed polycycles with putative anti-influenza A activity. 
 
9.1. Synthetic route 
 
 The V and VI families were synthesized in parallel [61].  The synthesis 
started with the reaction of maleimide with either cycloheptatriene (for the 
preparation of V) or cyclooctatetraene (for the preparation of VI) in a heated 
sealed tube. Interestingly, in this reaction –previously reported by                
Abou-Gharbia and co-workers [62], the cyclooctatetraene, 19, under high 
temperatures, isomerizes to its valence isomer bicyclo[4.2.0]octa-2,4,7-
triene, 20, by means of a thermal 6e
-
 electrocyclic pericyclic reaction                
[63-65]. This in situ formed specie is the diene that reacts with the dienophile 
maleimide in the subsequent Diels-Alder reaction, yielding the tetracyclic 
endo-adduct 21. 
 
 
 
Scheme 3. Synthetic route to 4-azatetracyclo[5.4.2.02,6.08.11]tridecane derivatives 
with antiviral activity. The ring-contracted analogues derived from V were 
synthesized using the same synthetic route but starting from cycloheptatriene [61]. 
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 A double reduction of the imide 21 carbonyl groups using Red-Al
®
, 
lead to the first bioactive product, the pyrrolidine 22. From this key 
intermediate 22 the desired saturated derivative, 24, and their 
corresponding guanidines, 23 and 25, were easily accessed through an 
hydrogenation with Pd/C as catalyst and a reaction with 1H-pyrazole-1-
carboxamidine, respectively. 
 
 
 
Scheme 4. Synthesis of the third generation: 28 and 29, triple inhibitors of the wt, 
V27A and L26F mutant channels of influenza A [61]. 
 
 We were aiming to improve our previous results and, for this, in our 
third generation we designed a structurally unrelated scaffold which was 
wider and longer in respect to amantadine’s structure. Following this 
idea the family VII was prepared. Starting from the known imide 26, this 
molecule gave access to the new pentacyclic core in only one step, which 
involved a [2+2] photocycloaddition under UV light. Even the 36% yield 
of this step was relatively low, the rapid access to the desired VII 
scaffold shift the balance positively towards this synthetic strategy. Upon 
isolation of imide 26, the usual synthetic path yielded amine 28 and 
guanidine 29. 
 
9.2. Pharmacological evaluation 
 
 The inhibitory activity of the compounds was tested on A/M2 channels 
expressed in Xenopus oocytes using the two-electrode voltage clamp 
(TEVC) technique. Regarding the second-generation compounds (scaffolds 
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V and VI in Figure 7), the four derivatives of scaffold VI (amines 22 and 
24 and guanidines 23 and 25) and their corresponding analogues derived 
from scaffold V were low micromolar inhibitors of the wt channel               
(e.g., IC50 = 16.0 and 1.2 M for Amt and 24, respectively). Regarding the 
activity against the V27A M2 mutant channel, three trends were found, 
i.e., guanidine performed better than its corresponding amine, the fully 
saturated compounds were more potent than their corresponding 
unsaturated analogues, and the derivatives of V were less potent than the 
ring-expanded derivatives of VI. Not unexpectedly, the larger compound 
from this series, guanidine 25, was the more promising compound, being 
more potent than Amt against the wt M2 channel (IC50 = 2.1 M) and 
endowed with fair activity against the V27A mutant channel (IC50 = 22.6 M). 
Overall, this second generation compounds led to dual inhibitors in very 
short synthetic routes [61]. 
 The next challenge, to be able to target more mutant channels while 
keeping very short synthetic sequences, was achieved with the third 
generation of inhibitors (scaffold VII, Figure 7 and Scheme 4). Strikingly, 
we could report, for the first time in the literature, potent triple inhibitors 
lacking the adamantane scaffold. Thus, our new compounds 28 and 29 were 
able to potently inhibit at once three different M2 channels: the wt and the 
mutants V27A and L26F. On the top of that, 28 and 29 were equipotent to 
amantadine for the wt and clear superior inhibitors of the V27A and the 
L26F mutant. 
 In addition, this unforeseen activity prompted an in-depth study of 28 
binding mode by Prof. F. J. Luque and co-workers. Through molecular 
dynamics simulations, a clear difference between the binding of this amine 
28 in the wt or in the V27A mutant channel could be spotted. Meanwhile in 
the wt the binding occurred with the basic group pointing towards the viral 
interior –the so called down binding mode- paralleling the one that Amt 
displays; in the case of the V27A this compound is found in equilibria 
between the down binding mode and the up binding mode – where the 
basic moiety points towards the viral exterior. The key feature for this 
compound to be stabilized in the up binding mode, preventing its rapid 
release to the cytoplasm, was found to be the four methyl substituents 
placed in the upper part of the molecule [61]. 
 The presented families show the feasibility of designing easily 
accessible compounds able to successfully inhibit the wt and the V27A and 
L26F variants of the A/M2 channels of influenza A virus. In fact, some of 
the newly designed compounds inhibit the three channels similarly or even 
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more effectively than Amt inhibits the wt proton channel. In particular, 
amine 28 and guanidine 29 emerged as promising compounds, being low 
micromolar inhibitors against the wt channel and the L26F mutant, while 
being endowed with submicromolar IC50 against the V27A variant. 
Furthermore, compound 28 showed strong activity against the A/PR/8/34 
strain, an A/H1N1 virus with two mutations (S31N and V27T) in the M2 
protein. However, taking into account that this compound was devoid of 
activity against the S31N M2 mutant channel, this activity must be related 
with an alternative mechanism of action, as we and others have 
comprehensively discussed [66-67]. Overall, these results suggest that 
compounds 28 and 29 are suitable templates to explore novel candidates 
against influenza virus. 
 
wild type channel
“down” binding mode
V27A mutant channel
“down” binding mode “up” binding mode
 
 
Figure 8. Amine 28 bound to the wt (“down” bonding mode) and the V27A mutant 
channels (“down” and “up” binding modes). For clarity, only 3 chains are shown. 
 
10. Fourth generation inhibitors 
 
 Regardless our previous efforts in the anti-influenza research line had 
been mainly oriented to replace the adamantane scaffold by a more suitable 
polycycle [50,52,61], the disclosure of several M2 channel structures with 
bound amantadine [19,58,68] or adamantane containing compounds [69], 
provided new detailed insights of the binding mode of adamantane-like 
molecules. Hence, we decided to take advantage of this recent knowledge 
to, building up on our expertise, design adamantane related compounds 
with improved features to display an upgraded inhibition profile.  
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Figure 9. Anti-influenza adamantyl compounds: spiro compound 30, piperidines 31 
and 32 and the novel envisaged analogue 33. aEC50 determined in the influenza 
A/HongKong/7/87/H3N2 strain, which carries a wt channel. 
 
 In line with this, DeGrado’s group disclosed in 2011 the                           
spiro compound  30, which shows an outstanding activity against the V27A, the 
L26F mutant and the wt M2 channels [70]. Worthy of note,             
Kolocouris et al. had previously reported the synthesis of 32, an adamantyl 
piperidine related to 30 [71], which failed to show activity against an 
Influenza strain carrying an Amt-resistant S31N mutant M2 channel 
(A/X31, H3N2), and its isomeric piperidine 31 [72-73] that was found to 
be active against an strain containing a wt M2 channel 
(A/HongKong/7/87/H3N2). They also showed that the lowest energy 
conformation of 32, resulted in a geometry quite different that the one 
shown by the amines 30 and 31. These facts made us question the 
importance of the basic centre position in the molecule; hence, in our new 
designs we orientated this polar group towards the terminal histidines and 
perpendicular to the protein backbone, analogously to 30 (Figure 9).   
 To further address the basic centre orientation remark, besides 
modifying the position of the nitrogen atom in the piperidine ring, we 
decided to investigate which was the most suitable anchoring point for this 
ring, in the adamantane scaffold. For this we prepared two series of 
adamantyl piperidine analogues bearing the heterocycle in the adamantane 
C1 (as in amantadine) or C2 (as in the triple inhibitor 30) positions [74]. 
Our designs were first studied in silico by Luque’s group. Their theoretical 
calculations indicated that our compounds were very similar to 30, so their 
increased length with respect to Amt could provide an improvement of the 
inhibitory activity. 
 In light of those predictions we decided to prepare an extra series of  
C-2 analogues featuring a methylene group between the lipophilic core and 
the ring, displaying even longer scaffolds. 
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10.1. Synthesis 
 
 First we undertook the synthesis of the C-1 series. Paralleling the work 
of Togo and coworkers [75], the isomeric mixture of the pyridine 
derivatives 44 and 45 was readily obtained after the radical 
decarboxylation of the carboxylic acid 43 in the presence of pyridine. In 
this reaction the first step is the acid‐base exchange between the 
1‐adamantane carboxylic acid and the pyridine. Next, the 
[bis(trifluoroacetoxy)iodo]benzene reacts with the in situ generated 
adamantane carboxylate,  displacing  the  trifluoroacetate moieties, to give 
[bis(1‐adamantanecarboxyl)iodo]benzene. This species undergoes a radical 
decarboxylation to generate an adamantly radical, which adds to  the  
pyridinium  cation  that  finally,  rearomatizes  to  yield  the  desired  
addition  products 35 and 36. 
 After a simple chromatography separation of both isomers, a catalytic 
hydrogenation with platinum oxide (IV) as catalyst, yielded the desired 
piperidines 37 and 38. The usual guanidine derivative was build up for 37, 
in a 76% yield. Despite our several attempts, the analogous reaction over 
the piperidine 38 was repeatedly unsuccessful, presumably reflecting the 
greater steric congestion around this nitrogen atom (Scheme 5). 
 
 
 
Scheme 5. Synthesis of 4-(1-adamantyl)piperidines. aReagents and conditions:                       
a: pyridine, [bis(trifluoroacetoxy)iodo]benzene, anh. benzene, reflux, overnight, 35, 
9%; 36, 27%; b: H2, PtO2, MeOH, 30 atm, 97% yield for 37; 99% yield for 38;                  
c:  1H-pyrazole-1-carboxamide hydrochloride, anh. Et3N, acetonitrile, reflux, 6 h, 
76% yield. 
 
 After this, the compounds belonging to the C-2 series were prepared 
(Scheme 6). The preparation of both series was envisaged through the same 
synthetic sequence starting with the addition to 2-adamantanone of the 
corresponding in situ generated organolithium reagent, 4-pyridil lithium or 
4-picolinyl lithium, respectively. The formed adamantyl pyridine species 
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was then hydrogenated using platinum oxide as catalyst, to give the first 
bioactive compound (33 and 46). The tertiary alcohol group of 46 was 
eliminated to yield olefin 47 that was further hydrogenated using 10% 
palladium over active charcoal as catalyst to give the saturated analogue 48. 
The saturated compounds, 33 and 48 were converted to tertiary amines 
through a reductive alkylation reaction with acetaldehyde or formaldehyde, 
to furnish 44 and 49, respectively. Finally, amines 47 and 48 reacted with 
1H-pyrazole-1-carboxamidine hydrochloride furnishing the guanidine 
derivatives 50 and 51, respectively [74]. 
 
 
 
Scheme 6. Synthetic route for the preparation of the adamantyl piperidine C-2 series. 
Reagents and conditions: a: 4-pyridyl lithium; Et2O/THF, -65 °C to rt, 70% yield;             
b: 1 atm H2, PtO2, ethanol, rt, 24 h, 93% yield of a mixture of 42, 43 and 33;                      
c: 1) SOCl2, pyridine, anh. CH2Cl2, -60 °C, 30 min, 2) 1 atm H2, Pd/C, methanol, HCl, 
rt, 2 h, 63% overall yield; d: acetaldehyde, NaCNBH3, AcOH, methanol, rt, 24 h, 76% 
yield; e: 4-picoline, anh THF, n-BuLi, 2 h, rt, 90% yield; f: 1 atm H2, PtO2, HCl, 
methanol, 5 days, > 99% yield; g: SOCl2, pyridine, anh. CH2Cl2, -60 °C, 30 min, > 99% 
yield;  h: 1H-pyrazole-1-carboxamidine hydrochloride, anh Et3N, acetonitrile, 70 °C,              
6 h, 88% yield for 50, 64% yield for 51; i: 1 atm H2, Pd/C, methanol, HCl, rt, 2 h, 68% 
yield; j: formaldehyde (37% aqueous solution), NaCNBH3, AcOH, rt, 18 h, 73% yield. 
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Table 1. Pharmacological assays in M2/wt wrap up. aIsochronic (2 min) values for 
IC50 are given. 
bTEVC technique in Xenopus oocytes. cEC50 based on 72-h compound 
exposure time. 
 
 
Influenza A wt    IC50                                                                                        EC50 
 µM
 a
 Kinetics
b
    µM
 c
 
 
16.0  
 
0.2  
 
 
4.1 
 
0.2  
 
 
ND 
 
0.8  
 
 
1.9 
 
 
 
>50 
 
   
10.2. Pharmacological evaluation 
 
 As in previous series, the antiviral activities and the channel blocking 
abilities of the new compounds were measured; this time, however, further 
TEVC assays, to assess the kinetics of the M2 channel inhibitors were 
carried out (Table 1 and Table 2) [74]. From these results a lack of 
correlation was observed between those coming from the isochronic 
inhibition assays, in which several compounds displayed potent M2 
blockade (both on the wt and the V27A M2 mutant channel), and the 
antiviral activity assays, in which a reduced number of our molecules were 
identified as antivirals. Steaming from these observations we could 
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experimentally prove the V27A resistance mechanism previously proposed 
in silico and through NMR studies. 
 In table 1 it can be seen that only the compounds with slow Koff (as 
Amt, 37 and 38) display antiviral activity, regardless their channel 
blocking ability. The importance of slowly leaving the channel before the 
rate of binding to it, can be seen when comparing 39, which displays M2 
blockade at 2 min but not antiviral activity, and 38, that does not block the 
channel upon short exposure, due to a slow Kon, but displays antiviral 
activity (because of slow Koff). 
 
Table 2. Pharmacological assays in M2/V27A wrap up. aIsochronic (2 min) values 
for IC50 are given. 
bTEVC technique in Xenopus oocytes. cEC50 based on 72-h 
compound exposure time. NA = Not active. ND = EC50 not determined. 
 
 
Influenza A          IC50                                                                                      EC50 
V27A µM
 a
 Kinetics
b
   µM
 c
 
 
> 500 
 
NA 
 
 
3.6  
 
ND 
 
 
> 500 
 
NA 
 
 
16.2  
 
NA 
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 The main evidence for the mechanism of resistance of the V27A 
mutant M2 channel is the behaviour of amine 37. This compound is able 
to block both the wt (IC50 = 4.1 M) and the V27A mutant (IC50 = 3.6 M) 
M2 channels in the typical TEVC experiments (2 min). However, for the 
V27A mutant, the block is only maintained for a short time, because 
weak binding affinity facilitates dissociation during washing with            
drug-free pH 8.5 buffer, after which the blocker is released from the 
channel that becomes functional again. This fact explains why 37 is 
active as antiviral against a strain carrying the wt channel but lacks 
activity against a strain carrying the V27A mutant M2 channel (compare 
Table 1 and 2) [74]. Our new experimental evidence for V27A drug 
resistance reinforces the previous computational [76-80] and structural 
[59] hypothesis and may lead to a more profound comprehension on how 
Influenza A virus acquires resistance, to eventually shed light to drug 
design. 
 
11. Conclusion 
 
 Overall our research has allowed to move from Amt, inactive against 
the three main mutants, to potent dual inhibitors with a complex 
synthesis (first generation) which was later on simplified reaching potent 
dual inhibitors in only two synthetic steps (second generation). 
Following the most potent triple inhibitor at the time, was accessed in 
few synthetic steps and featuring an unforeseen polycyclic scaffold (third 
generation). Finally with the fourth generation the in silico predicted 
drug resistance mechanism of the V27A mutant channel, could be 
demonstrated. 
 We hope that all these findings, along with the recent paramount 
advances on the understanding of the proton conductance mechanisms  
[81-85] and mutant M2 channels structure [86-87] will bring the 
antiinfluenza A drug research closer to the discovery of a suitable drug to 
fight the virus [88-93]. 
 Finally is worth mentioning the combined antiviral therapy has 
raised great interest as a strategy to fight the influenza virus [94-95]. 
Similar to the antiretroviral therapy, this will consist in the 
administration of a drug cocktail that will target different steps of the 
viral cycle. We believe that the drugs targeting the viral protein HA will 
be excellent allies to the M2 blockers for this purpose [96].   
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